(202) 599-8435

CLAAD Presents Testimony Encouraging FDA Panel’s To Apply REMS Safety Measures

fda logoEarlier this week, CLAAD presented testimony before a meeting of the U.S. Food and Drug Administration’s (FDA) Drug Safety and Risk Management Advisory Committee. The committee reviewed comments regarding the Risk Evaluation and Mitigation Strategy (REMS) for extended-release and long-acting opioid analgesic medications. CLAAD, represented by Policy Advisor, Shruti Kulkarni, urged the committee to apply REMS safety measures to reduce misuse and abuse to immediate-release opioids, as well as controlled medications in other drug classes. Additionally, CLAAD clarified its support for mandatory prescriber training on responsible prescribing practices, and reiterated the REMS Program Companies’ recommendation that federal agencies like FDA and the National Institute on Drug Abuse work together to develop consistent professional education curricula. Click here to read CLAAD’s full testimony.

Print Friendly
About the Author